AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01337167 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq™
Description: RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
Study NCT01337167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™
Description: RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
Study NCT03824392 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Efzofitimod 1.0 mg/kg or Placebo
Description: Participants to receive efzofitimod 1.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
Study NCT03824392 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efzofitimod 3.0 mg/kg or Placebo
Description: Participants to receive efzofitimod 3.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
Study NCT03824392 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Efzofitimod 3.0 mg/kg or Placebo
Description: Participants to receive efzofitimod 3.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
Study NCT03824392 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efzofitimod 5.0 mg/kg or Placebo
Description: Participants to receive efzofitimod 5.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
Study NCT01337167 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PENTACEL™
Description: PENTACEL™ 0.5 mL intramuscular injection at 2, 4, and 6 months of age
Study NCT03824392 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Efzofitimod 5.0 mg/kg or Placebo
Description: Participants to receive efzofitimod 5.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
Study NCT03925987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Description: 10 weekly sessions of group-based exposure therapy
Study NCT01282866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LightSheer Duet
Description: LightSheer Duet HS handpiece
Study NCT02289469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PictureRx medication history platform
Description: Tablet PC-based tool to take more complete and accurate medication history
Study NCT00105664 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collaborative care model
Study NCT00105664 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Group interventions
Study NCT00105664 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Facilitated consultation
Study NCT03053778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early follow-up
Description: Early follow-up until 4 weeks after discharge
Study NCT01337167 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombivax HB vaccine
Description: Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
Study NCT01337167 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB™
Description: ActHIB™ 0.5 mL intramuscular injection at 15 months of age
Study NCT02201355 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy
Description: Patients treated five fractions per week with radiotherapy dose per fraction and cisplatin dose increased according to the treatment table
Study NCT03010943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset
Description: Feasibility and tolerance
Study NCT02449941 — intervention group
Intervention type: DRUG
Intervention: PPI (proton pump inhibitor)
Description: 1. Pre ESD (endoscopic submucosal dissection)~   * Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~  * Use of PPI for 2 months~2. Post ESD 1 (After 2 months)~   * Assess the distribution of helicobacter pylori after using PPI.~  * Stop of PPI~3. Post ESD 2 (After 4 months)~   * Assess the distribution of helicobacter pylori after stop of PPI.
Study NCT01754077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LENA Linguistic Feedback Reports
Description: LENA feedback reports show hourly/daily estimates for AWC/CTC and TV/electronic media. The feedback reports will include data obtained from LENA home audio recordings that the families complete. Feedback reports are only given to parents for 8 weekly recordings. The parent does not receive a feedback report for the baseline recordings or the follow-up recordings.
Study NCT01754077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Visiting Educational Session
Description: A research assistant visited the homes of the participants to discuss strategies, skills, and barriers related to enriching children's language environments. The visits included a multi-media educational module, video modeling exercise, goal setting, and linguistic feedback report review. There were 8 weekly home visits in the intervention program.
Study NCT01754077 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Childhood Nutrition Education
Description: The childhood nutrition education intervention is a brief home-visiting intervention during which parents receive information on nutrition from a research assistant. The intervention mirrored the experimental group's educational intervention and decreased the likelihood of differences between groups being the result of attentional effects. This intervention is received by the control group.
Study NCT04457570 — intervention group
Intervention type: OTHER
Intervention: mortality
Description: To measure the excess risk of mortality of patients with a history of cancer among patients hospitalized for a SARS-CoV-2 infection
Study NCT01185704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix acetate
Description: Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 1 (Day 0 of stimulation period \[S0\]) until r-hCG day (at least 2 follicles >=17 mm)
Study NCT01185704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix acetate
Description: Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 7 (Day 6 of stimulation period \[S6\]) until r-hCG day (at least 2 follicles >=19 mm)
Study NCT01185704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Choriogonadotropin (r-hCG)
Description: The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day
Study NCT01185704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human follicle stimulating hormone (r-hFSH)
Description: Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period \[S1\]) until r-hCG day
Study NCT02494154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo 2; Ficher and Paykel HealthCare
Description: High flow nasal cannulas
Study NCT02494154 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen delivery via conventional nasal mask
Description: Low flow of oxygen delivered through conventional nasal prongs
Study NCT01897493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally
Study NCT01897493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Administered orally
Study NCT01897493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administered orally
Study NCT00803361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 60 to 120 mg, capsules, oral, once a day for 15 weeks
Study NCT00803361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules, oral, once a day for 15 weeks
Study NCT06268587 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Measure the impact of the home analgesia protocol on the proportion of patients with a VAS &amp;gt; 3/10 on day one and who did not take analgesics.
Description: Measure the impact of the home analgesia protocol on the proportion of patients with a VAS \&amp;gt; 3/10 on D+1 and who did not take analgesics. The protocol consists of providing the patient with instructions at the time of discharge, analgesics for a maximum of two days with dosages and an explanatory booklet on pain management
Study NCT03593733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation Therapy
Description: Photobiomodulation Therapy
Study NCT03593733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion
Description: Cold Water Immersion
Study NCT02906891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vigilant Diabetes Management Application
Description: The Vigilant Diabetes Management Companion by InSpark Technologies was developed to assist in the prevention of hypoglycemia by providing the individual with an unobtrusive analysis of their blood glucose values and notifying them about periods of upcoming risk for low and high blood glucose; and in particular periods of risk for severe hypoglycemia. This allows the individual to take preventive corrective action. Subjects will download the Vigilant DiabetesManagement Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
Study NCT03434652 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous neurostimulation
Description: Auricular percutaneous neurostimulation
Study NCT03434652 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Percutaneous neurostimulation
Description: Auricular percutaneous neurostimulation
Study NCT01251302 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Corus CAD (ASGES)
Description: Age/Sex/Gene Expression Score - ASGES
Study NCT03036111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimebutine
Description: Trimebutine suppository will be inserted in the anal canal on completion of hemorrhoidectomy then at six and 12 hours postoperatively.
Study NCT03036111 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Hemorrhoidectomy
Description: Patients will undergo classic Milliagn-Morgan hemorrhoidectomy
Study NCT03036111 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemorrhoidectomy
Description: Patients will undergo classic Milliagn-Morgan hemorrhoidectomy
Study NCT03522194 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: Anesthesia maintenance with Sevoflurane
Study NCT03522194 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Anesthesia maintenance with Propofol
Study NCT02079051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity weight loss
Description: A calorie restricted diet based on estimates of total energy expenditure (TEE) obtained from the measured resting metabolic rate (RMR) during a wt stable period. TEE will be estimated by multiplying RMR by a factor of 1.1-1.3 to cover activity energy expenditure based on an assessment of physical activity levels at baseline using accelerometry. We will use the TEE to create an individualized dietary rx for each pt, subtracting up to 500 calories from the estimated TEE. To ensure micronutrient needs are being met, total calories will not be decreased below 1200 kcal per day, regardless of the estimated TEE. They will receive a standard exercise program that will be designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per week.
Study NCT02079051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity medical weight loss
Description: Placed on complete meal replacement (MR) using the OPTIFAST medical wt loss protocol. Pts will consume a min of 86 g of protein daily in 5-6 servings of MR. Min caloric intake will be 960 kcal/day with adjustments in intake made based on BMI and activity levels, holding the percent of calories from protein constant at 35%. The MRs provide 100% of daily recommended needs for micronutrients and will be supplied weekly at clinic visits by the study. Pts will begin to incorporate food into their routine beginning at week 13 with guidance from a dietitian. From weeks 13-26, caloric prescriptions will be between 1100 to 1600 kcal/day, using a combo of MRs and food. Will receive an exercise program designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per wk.
Study NCT03565172 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: isokinetic dynamometer with ultrasound
Description: children are lying prone on a isokinetic dynamometer with ultrasound which stretches spastic and paretic plantarflexors muscles very slowly until maximal torque tolerated. The parameters can be measured.
Study NCT03565172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Description: the discomfort level will be measured by Visual Analog Scale (VAS) completed by children. 0 = no discomfort and 10 = maximum discomfort
Study NCT03565172 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stretching
Description: the ankle of children will be mobilized for 5 minutes (first two weeks) to 10 minutes (last two weeks).
Study NCT02757807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Utilization of Serenita for Relaxation
Description: Users to use Serenita daily and before sexual interaction in order to assess stress and reduce it
Study NCT03966040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7
Description: 36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7
Study NCT03966040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7
Description: 36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7
Study NCT03674814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be taken by mouth at assigned dose. Enzalutamide will be obtained as standard of care prescription (not provided by study).
Study NCT03674814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant
Description: Relacorilant will be taken by mouth at assigned dose. Relacorilant will be provided by the study.
Study NCT04454151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Tablets
Description: given PO Azithromycin 250 mg X1 daily, for 4 months, followed by a non-treatment follow-up period of 12 month.
Study NCT01406223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Study NCT00383578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg qd
Study NCT00383578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 1500 mg daily
Study NCT02376595 — intervention group
Intervention type: DRUG
Intervention: Rocuronium Bromide
Description: Rocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus.
Study NCT04401397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive early mobilization techniques
Description: Pulmonary techniques: lung mechanics and breathing pattern restoration, mucus clearance techniques, breathing control and cough techniques.~Musculoskeletal techniques: strengthening and functional exercises, active assistive moving techniques.
Study NCT04401397 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive early mobilization techniques
Description: Pulmonary techniques: lung mechanics and breathing pattern restoration, mucus clearance techniques, breathing control and cough techniques.~Musculoskeletal techniques: strengthening and functional exercises, active assistive moving techniques.
Study NCT06402279 — intervention group
Intervention type: DEVICE
Intervention: Efferon CT
Description: Efferon CT is a cylindrical body made of polycarbonate, filled with spherical granules of polymer hemocompatible macroporous styrene-divinylbenzene copolymer of super cross- linked type and isotonic sodium chloride solution. The device is manufactured according to TU 32.50.50-001-12264678-2018, has passed the necessary tests and is registered in Russia as a medical product RZN 2019/8886.~Hemoperfusion procedures were performed using the Efferon CT device no later than 6 hours after the start of invasive ventilation. Hemosorption was performed twice within 12 hours, with an interval of 24 hours between hemoperfusion.
Study NCT03966040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7
Description: 36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7
Study NCT03966040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14
Description: 36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14
Study NCT03683368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YpsoPump Orbit micro
Description: Insulin infusion sets will be used for up to 7 days or until failure
Study NCT03660293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: cardio-protective agents
Study NCT03660293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril
Description: cardio-protective agents
Study NCT03660293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: cardio-protective agents
Study NCT03143608 — intervention group
Intervention type: DEVICE
Intervention: Esophyx
Description: Laparoscopic hiatal hernia repair followed immediately by transoral incisionless fundoplication under general anesthesia using the Esophyx device
Study NCT01177059 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: OZ1 transduced cells
Description: Long term follow up of previously infused OZ1 transduced cells
Study NCT03071094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pexastimogene Devacirepvec (Pexa Vec)
Description: Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 10\^9 pfu at day 1 and weeks 2 and 4
Study NCT03071094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered intravenously every 2 weeks (from week 2)
Study NCT00955136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of intermittent high MI impulses during echocardiogram
Description: Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
Study NCT02450708 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: KIR genotyping
Study NCT02450708 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HLA genotyping
Study NCT02401802 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-residue diet
Description: Subjects will be instructed by members of the research team to follow a standardized low residue diet for 4 days
Study NCT00477295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide
Description: Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
Study NCT00477295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
Study NCT00960115 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25)
Description: After receiving a single low-dose cyclophosphamide, participants will receive weekly subcutaneous vaccinations with tecemotide (L-BLP25) (930 microgram \[mcg\]) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with tecemotide (L-BLP25) (930 mcg) will be administered every 6 weeks until progressive disease (PD).
Study NCT00960115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single low dose cyclophosphamide
Description: A single intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg/m\^2) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
Study NCT00960115 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After receiving single dose of saline, participants will receive weekly subcutaneous vaccinations with placebo that matches with tecemotide (L-BLP25) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with placebo will be administered every 6 weeks until PD.